Global Exparel Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Exparel Market Research Report 2024
Liposomal bupivacaine has been approved by the US Food and Drug Administration for local infiltration for pain relief after bunionectomy and hemorrhoidectomy.
According to Mr Accuracy reports new survey, global Exparel market is projected to reach US$ 930.1 million in 2029, increasing from US$ 623 million in 2022, with the CAGR of 5.2% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Exparel market research.
Liposomal Bupivacaine gained significant attention and adoption in the medical field due to its potential to reduce the need for opioids for post-operative pain control. This aligns with efforts to combat the opioid epidemic by providing alternative pain management strategies.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Exparel market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Pacira Pharmaceuticals
Segment by Type
20ml
10ml
Veterinary
Human
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Exparel report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Exparel market is projected to reach US$ 930.1 million in 2029, increasing from US$ 623 million in 2022, with the CAGR of 5.2% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Exparel market research.
Liposomal Bupivacaine gained significant attention and adoption in the medical field due to its potential to reduce the need for opioids for post-operative pain control. This aligns with efforts to combat the opioid epidemic by providing alternative pain management strategies.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Exparel market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pacira Pharmaceuticals
Segment by Type
20ml
10ml
Segment by Application
Veterinary
Human
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Exparel report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source